PharmaShots’ Key Highlights of First Quarter 2024

Shots:The first quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Gilead's acquisition of CymaBay Therapeutics for an aggregate of ~$4.3BThis quarter also showcased multiple clinical trial results including Axsome Therapeutics P-III results for AXS-12 and BMS'…

BySenior EditorApril 1, 2024

INSIGHTS+

Know Your Investor (January Edition): RA Capital Management LLC  

Shots:  New Year, New Us! Our hand-curated “Know Your Investor” reports will now be exploring leading investors of 2023  Founded in 2002, RA Capital forged ahead to become a key investor in life science and healthcare companies. In 2023, RA Capital closed 40 major investments in biopharma companies, devices, manufacturing, service offering firms, and diagnostics  …

BySenior EditorJanuary 31, 2024

PharmaShots’ Key Highlights of First Quarter 2024

Know Your Investor (January Edition): RA Capital Management LLC

Contact US

OUR INFORMATION

FOLLOW US